Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Leo Pharma prepares novel CaS receptor agonists

June 26, 2012

EMA committee issues opinion on taliglucerase alfa

June 25, 2012

Ongoing meeting features presentations on PTHrP analogue for postmenopausal osteoporosis

June 25, 2012

Results from several dapagliflozin trials disclosed

June 25, 2012

Novel urate-lowering compound shows potential as a treatment for gout

June 25, 2012

Danish company divulges novel CaS receptor agonists

June 25, 2012

Novo Nordisk to begin phase III program for once-weekly GLP-1 analogue

June 22, 2012

IRM and Novartis team up to design novel FGF-21 variants

June 22, 2012

New GPR119 receptor agonists patented by Pfizer

June 22, 2012

Lupin presents novel candidate diabetes therapies

June 22, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...